Preparation of Novel Solid Phase Extraction Sorbents for Polycyclic Aromatic Hydrocarbons (PAHs) in Aqueous Media.

In this study, functionalized mesoporous silica was prepared and characterized as a stationary phase using various analytical and solid-state techniques, including a Fourier-transform infrared (FTIR) spectrometer, thermogravimetric analysis, and nitrogen sorption. The results confirmed the successful synthesis of the hybrid stationary phase. The potential of the prepared hybrid mesoporous silica as a solid-phase extraction (SPE) stationary phase for separating and enriching polycyclic aromatic hydrocarbons (PAHs) in both spiked water samples and real water samples was evaluated. The analysis involved extracting the PAHs from the water samples using solid-phase extraction and analyzing the extracts using a two-dimensional gas chromatograph coupled to a time-of-flight mass spectrometer (GC × GC-TOFMS). The synthesized sorbent exhibited outstanding performance in extracting PAHs from both spiked water samples and real water samples. In the spiked water samples, the recoveries of the PAHs ranged from 79.87% to 95.67%, with relative standard deviations (RSDs) ranging from 1.85% to 8.83%. The limits of detection (LOD) for the PAHs were in the range of 0.03 µg/L to 0.04 µg/L, while the limits of quantification (LOQ) ranged from 0.05 µg/L to 3.14 µg/L. Furthermore, all the calibration curves showed linearity, with correlation coefficients (r) above 0.98. Additionally, the results from real water samples indicated that the levels of individual PAH detected ranged from 0.57 to 12.31 µg/L with a total of 44.67 µg/L. These findings demonstrate the effectiveness of the hybrid mesoporous silica as a promising stationary phase for solid-phase extraction and sensitive detection of PAHs in water samples.

Population pharmacokinetic and pharmacodynamic properties of intramuscular quinine in Tanzanian children with severe Falciparum malaria.

Although artesunate is clearly superior, parenteral quinine is still used widely for the treatment of severe malaria. A loading-dose regimen has been recommended for 30 years but is still often not used. A population pharmacokinetic study was conducted with 75 Tanzanian children aged 4 months to 8 years with severe malaria who received quinine intramuscularly; 69 patients received a loading dose of 20 mg quinine dihydrochloride (salt)/kg of body weight. Twenty-one patients had plasma quinine concentrations detectable at baseline. A zero-order absorption model with one-compartment disposition pharmacokinetics described the data adequately. Body weight was the only significant covariate and was implemented as an allometric function on clearance and volume parameters. Population pharmacokinetic parameter estimates (and percent relative standard errors [%RSE]) of elimination clearance, central volume of distribution, and duration of zero-order absorption were 0.977 liters/h (6.50%), 16.7 liters (6.39%), and 1.42 h (21.5%), respectively, for a typical patient weighing 11 kg. Quinine exposure was reduced at lower body weights after standard weight-based dosing; there was 18% less exposure over 24 h in patients weighing 5 kg than in those weighing 25 kg. Maximum plasma concentrations after the loading dose were unaffected by body weight. There was no evidence of dose-related drug toxicity with the loading dosing regimen. Intramuscular quinine is rapidly and reliably absorbed in children with severe falciparum malaria. Based on these pharmacokinetic data, a loading dose of 20 mg salt/kg is recommended, provided that no loading dose was administered within 24 h and no routine dose was administered within 12 h of admission. (This study has been registered with Current Controlled Trials under registration number ISRCTN 50258054.).

Measurement of lumefantrine and its metabolite in plasma by high performance liquid chromatography with ultraviolet detection.

Artemether-lumefantrine (ARM-LUM) has in recent years become the first-line treatment for uncomplicated malaria in many Sub-Saharan African countries. Vigorous monitoring of the therapeutic efficacy of this treatment is needed. This requires high-quality studies following standard protocols; ideally, such studies should incorporate measurement of drug levels in the study patients to exclude the possibility that insufficient drug levels explain an observed treatment failure. Several methods for measuring lumefantrine (LUM) in plasma by HPLC are available; however, several of these methods have some limitations in terms of high costs and limited feasibility arising from large required sample volumes and demanding sample preparation. Therefore, we set out to develop a simpler reversed phase high performance liquid chromatography (RP-HPLC) method based on UV detection for simultaneous measurement of LUM and its major metabolite the desbutyl LUM (DL) in plasma. Halofantrine was used as an internal standard. Liquid-liquid extraction of samples was carried out using hexane-ethyl acetate (70:30, v/v). Chromatographic separation was carried out on a Synergi Polar-RP column (250 mm × 300 mm, particle size 4 µm). The mobile phase consisted of acetonitrile-0.1M ammonium acetate buffer adjusted to pH 4.9 (85:15%, v/v). Absorbance of the compounds was monitored at 335 nm using a reference wavelength of 360 nm. Absolute extraction recovery for LUM and DL were 88% and 90%, respectively. Inter- and intraday coefficients of variation for LUM and DL were ≤ 10%. The lower limits of quantification for LUM and DL were 12.5 and 6.5 ng/ml, respectively. After validation, the methodology was transferred to a local laboratory in Tanga Tanzania and samples from a small subset of malaria patients were analysed for LUM. The method appears to be applicable in settings with limited facilities.